Danaher Corporation (DHR - Free Report) yesterday announced that its dental subsidiary, Envista Holdings Corporation, priced its initial public offering of common shares at $22.00 per share. Subject to the fulfillment of closing conditions, the offering will close on Sep 20, 2019.
It is worth mentioning here that Danaher announced about this plan for initial public offering of Envista in June this year. Yesterday, Danaher’s share price increased 1.19%, closing the trading session at $142.33.
Inside the Headlines
The share offering comprises approximately 26.8 million common shares of Envista. Gross proceeds (before deduction of any expenses related to underwriting and offering) of roughly $588.9 million are anticipated from this offering. Danaher will be awarded the consideration, after payment of related expenses as part payment for its dental assets.
Also, the underwriters have been provided with an option to purchase an additional 4 million shares within 30 days. The purchase price for the underwriters will be adjusted for commissions and underwriting discounts.
Envista shares, under the ticker symbol “NVST”, will trade on the NYSE. Danaher’s shares in Envista will be roughly 82.7% or 80.6%, provided overallotment option is completely used by the underwriters.
Brief on Envista
Envista consists Danaher Dental segment's three operating businesses — Nobel Biocare Systems, Ormco and KaVo Kerr. These businesses specialize in dental equipment, orthodontics, dental implants and consumables. Some notable brands are Nobel Biocare, Kerr, i-CAT, KaVo, Dexis, Pelton & Crane, Metrex, Ormco, Implant Direct, and Orascoptic.
Envista provides services to dentists (more than one million) in as many as 150 countries. It employs 12,000 people.
Zacks Rank, Earnings Estimates and Price Performance of Danaher
With a market capitalization of approximately $100.9 billion, Danaher currently carries a Zacks Rank #2 (Buy). In the past 60 days, the Zacks Consensus Estimate for its earnings has risen 0.2% to $4.79 for 2019 and 4.1% to $5.59 for 2020.
Danaher Corporation Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Danaher Corporation (DHR - Free Report) yesterday announced that its dental subsidiary, Envista Holdings Corporation, priced its initial public offering of common shares at $22.00 per share. Subject to the fulfillment of closing conditions, the offering will close on Sep 20, 2019.
It is worth mentioning here that Danaher announced about this plan for initial public offering of Envista in June this year. Yesterday, Danaher’s share price increased 1.19%, closing the trading session at $142.33.
Inside the Headlines
The share offering comprises approximately 26.8 million common shares of Envista. Gross proceeds (before deduction of any expenses related to underwriting and offering) of roughly $588.9 million are anticipated from this offering. Danaher will be awarded the consideration, after payment of related expenses as part payment for its dental assets.
Also, the underwriters have been provided with an option to purchase an additional 4 million shares within 30 days. The purchase price for the underwriters will be adjusted for commissions and underwriting discounts.
Envista shares, under the ticker symbol “NVST”, will trade on the NYSE. Danaher’s shares in Envista will be roughly 82.7% or 80.6%, provided overallotment option is completely used by the underwriters.
Brief on Envista
Envista consists Danaher Dental segment's three operating businesses — Nobel Biocare Systems, Ormco and KaVo Kerr. These businesses specialize in dental equipment, orthodontics, dental implants and consumables. Some notable brands are Nobel Biocare, Kerr, i-CAT, KaVo, Dexis, Pelton & Crane, Metrex, Ormco, Implant Direct, and Orascoptic.
Envista provides services to dentists (more than one million) in as many as 150 countries. It employs 12,000 people.
Zacks Rank, Earnings Estimates and Price Performance of Danaher
With a market capitalization of approximately $100.9 billion, Danaher currently carries a Zacks Rank #2 (Buy). In the past 60 days, the Zacks Consensus Estimate for its earnings has risen 0.2% to $4.79 for 2019 and 4.1% to $5.59 for 2020.
Danaher Corporation Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on DHR - FREE
Get the latest research report on CSL - FREE
Get the latest research report on FSS - FREE